Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma
- PMID: 40718077
- PMCID: PMC12296707
- DOI: 10.2147/JHC.S523261
Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis. The Wnt/β-catenin signaling pathway is a key regulator of cellular proliferation, differentiation, and stem cell maintenance, and is frequently dysregulated in HCC, contributing to tumor progression, metastasis, and drug resistance. Natural bioactive compounds (NBCs) have emerged as promising treatments due to their multi-targeted mechanisms, low toxicity, and ability to modulate key oncogenic pathways. This review examines the potential of NBCs to target the Wnt/β-catenin pathway in HCC. Compounds such as curcumin, emodin, gallic acid, and ginsenosides exhibit anti-tumor effects by inhibiting β-catenin nuclear translocation, inducing autophagy, suppressing angiogenesis, and modulating the tumor microenvironment. For example, curcumin inhibits HCC cell proliferation and invasion by downregulating lncRNA expression and EMT markers, thereby inactivating the Wnt/β-catenin signaling pathway. Additionally, alkaloids like tetrandrine and toosendanin reduce metastasis through pathway-specific inhibition and epigenetic modulation. These compounds demonstrate potential as standalone therapies, and also in combination with conventional treatments like sorafenib by enhancing the effectiveness and overcoming resistance. However, challenges such as limited bioavailability, stability, and the intricate interplay of the Wnt/β-catenin pathway with other signaling pathways highlights the need for advanced delivery systems and combination strategies. In conclusion, future research should prioritize clinical validation, precision medicine approaches, and exploration of the role of NBCs in cancer stem cell regulation. Collectively, NBCs targeting the Wnt/β-catenin pathway offer a novel, safer, and multi-faceted approach for improving HCC treatment outcomes, paving the way for their integration into standard therapeutic regimens.
Keywords: Wnt/β-catenin signaling; cancer therapeutics; hepatocellular carcinoma; natural bioactive compounds; pathway modulation.
© 2025 Tian et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.J Gene Med. 2024 May;26(5):e3685. doi: 10.1002/jgm.3685. J Gene Med. 2024. PMID: 38686653
-
The effect of dendrosomal nanocurcumin on Wnt/β-catenin signaling pathway via PIWIL2 in MCF-7 breast cancer cells.Med Oncol. 2025 Jul 28;42(9):381. doi: 10.1007/s12032-025-02960-6. Med Oncol. 2025. PMID: 40719975
-
Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.Front Pharmacol. 2025 Aug 25;16:1626251. doi: 10.3389/fphar.2025.1626251. eCollection 2025. Front Pharmacol. 2025. PMID: 40926993 Free PMC article. Review.
-
Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma.Cell Death Dis. 2025 Jul 1;16(1):466. doi: 10.1038/s41419-025-07789-5. Cell Death Dis. 2025. PMID: 40593458 Free PMC article.
-
Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential.Front Pharmacol. 2025 Jul 1;16:1592395. doi: 10.3389/fphar.2025.1592395. eCollection 2025. Front Pharmacol. 2025. PMID: 40667502 Free PMC article. Review.
References
-
- Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410–420. - PubMed
Publication types
LinkOut - more resources
Full Text Sources